-
1 Comment
Novozymes A/S is currently in a long term uptrend where the price is trading 19.0% above its 200 day moving average.
From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Basic Materials sector with a price to sales ratio of 8.2.
Novozymes A/S's total revenue sank by 7.6% to $3B since the same quarter in the previous year.
Its net income has dropped by 29.1% to $654M since the same quarter in the previous year.
Finally, its free cash flow grew by 399.3% to $754M since the same quarter in the previous year.
Based on the above factors, Novozymes A/S gets an overall score of 3/5.
ISIN | DK0060336014 |
---|---|
CurrencyCode | EUR |
Exchange | F |
Industry | Specialty Chemicals |
Sector | Basic Materials |
Market Cap | 13B |
---|---|
Beta | 0.39 |
Dividend Yield | 1.7% |
Target Price | None |
PE Ratio | 26.14 |
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NZM2.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024